Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.

[1]  Y. Sun,et al.  SBF-1 exerts strong anticervical cancer effect through inducing endoplasmic reticulum stress-associated cell death via targeting sarco/endoplasmic reticulum Ca2+-ATPase 2 , 2014, Cell Death and Disease.

[2]  T. Brümmendorf,et al.  Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. , 2014, Drug discovery today. Technologies.

[3]  T. Kurosu,et al.  Inhibition of the PI3K/Akt/GSK3 Pathway Downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD Downregulates DNA Damage-Induced Chk1 Activation as Well as G2/M Arrest and Prominently Enhances Induction of Apoptosis , 2013, PloS one.

[4]  L. Platanias,et al.  BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide , 2013, Autophagy.

[5]  M. Bogyo,et al.  Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. , 2012, Blood.

[6]  Qiang Xu,et al.  SBF-1, a synthetic steroidal glycoside, inhibits melanoma growth and metastasis through blocking interaction between PDK1 and AKT3. , 2012, Biochemical pharmacology.

[7]  W. Qian,et al.  Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro , 2012, Acta Pharmacologica Sinica.

[8]  A. Hamilton,et al.  Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. , 2012, Blood.

[9]  R. Arceci,et al.  Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival , 2012 .

[10]  T. Holyoake,et al.  Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. , 2011, Blood.

[11]  Qiang Xu,et al.  Mitochondria-dependent apoptosis of activated T lymphocytes induced by astin C, a plant cyclopeptide, for preventing murine experimental colitis. , 2011, Biochemical pharmacology.

[12]  T. Cotter,et al.  Inhibition of Protein-tyrosine Phosphatase 1B (PTP1B) Mediates Ubiquitination and Degradation of Bcr-Abl Protein* , 2011, The Journal of Biological Chemistry.

[13]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[14]  Xiao-yan Deng,et al.  [Effect of ZD6474 on the proliferation of imatinib-resistant K562 cells]. , 2010, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[15]  S. D. Turner,et al.  Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway , 2009, Leukemia.

[16]  D. Cilloni,et al.  Imatinib resistance in CML. , 2009, Cancer letters.

[17]  M. Deininger,et al.  New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check , 2008, Expert opinion on investigational drugs.

[18]  M. Deininger,et al.  New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. , 2008, Expert opinion on investigational drugs.

[19]  M. Deininger,et al.  Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.

[20]  G. Bjørkøy,et al.  p62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy* , 2007, Journal of Biological Chemistry.

[21]  M. Vranic,et al.  Ubiquitinated-Protein Aggregates Form in Pancreatic β-Cells During Diabetes-Induced Oxidative Stress and Are Regulated by Autophagy , 2007, Diabetes.

[22]  N. Tonks,et al.  Protein tyrosine phosphatases: from genes, to function, to disease , 2006, Nature Reviews Molecular Cell Biology.

[23]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[24]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[25]  Y. Wang,et al.  Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development , 2005, Leukemia.

[26]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[27]  Hao Wu,et al.  23-oxa-analogues of OSW-1: efficient synthesis and extremely potent antitumor activity. , 2004, Angewandte Chemie.

[28]  D. Neuberg,et al.  Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Skorski,et al.  Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571 , 2002, Oncogene.

[30]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[31]  Shawn M. Sweeney,et al.  Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. , 2000, Blood.

[32]  B. Franza,et al.  Protein Tyrosine Phosphatase 1B Antagonizes Signalling by Oncoprotein Tyrosine Kinase p210 bcr-abl In Vivo , 1998, Molecular and Cellular Biology.

[33]  G. Zon,et al.  Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. , 1995, Blood.

[34]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[35]  Susan M. Watanabe,et al.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.

[36]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[37]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.